Health science reportsApr 20, 2026

Semaglutide’s safety, effectiveness, and practical use for weight loss in adults without diabetes

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

Semaglutide 2.4 mg appears to produce substantial weight loss in non-diabetic adults, but access, tolerability, and durability shape its real-world usefulness.

Evidence

This narrative review synthesized 27 studies from 2019-2025, including randomized trials, observational studies, and qualitative reports on semaglutide for weight management in adults without diabetes.

Caveat

The review reports gastrointestinal discontinuation, high out-of-pocket costs, supply limits, and weight regain after stopping, with a need for long-term durability and head-to-head incretin trials.

Simplified

BACKGROUND AND AIMS: The rising global prevalence of obesity has catalyzed the development of potent glucagon-like peptide-1 (GLP-1) receptor agonists. This narrative review evaluates the efficacy, safety, and practical considerations of injectable semaglutide for weight management, specifically in non-diabetic adults, a population where weight loss outcomes often differ from those seen in diabetic cohorts.

METHODS: Using information from PubMed, Scopus, and Web of Science, a thematic synthesis was carried out under the guidance of the SANRA procedural framework (2019-2025). The search used tirzepatide as a comparative benchmark and a particular Boolean string to target semaglutide efficacy in non-diabetic groups. To evaluate metabolic effects and practical obstacles, data from 27 studies including observational studies, randomized controlled trials (RCTs), and qualitative reports, were analytically combined.

RESULTS: In adults without diabetes, semaglutide (2.4 mg) shows better weight loss efficacy, with mean reductions of roughly 14.9% as opposed to 9.6% in diabetic groups. Significant improvements in cardiometabolic indicators and quality-of-life assessments were observed in addition to weight loss. Nevertheless, the main reason for stopping is still gastrointestinal side effects. Long-term therapeutic utility is greatly impacted by practical obstacles, such as high out-of-pocket expenses, worldwide supply limitations, and the possibility of weight gain after cessation.

CONCLUSION: Although semaglutide is a novel obesity disease-modifying medication, its effectiveness depends on how well it is incorporated into multimodal treatment plans. Even though its effectiveness has been shown, equitable public health implementation requires addressing structural issues and safety concerns, such as drug pricing models and insurance coverage. Long-term durability studies and head-to-head trials with next-generation incretins should be the top priorities for future research.

Key numbers

14.9%

Weight Loss Reduction

Average weight loss in non-diabetic adults using semaglutide.

9.6%

Weight Loss in Diabetic Groups

Average weight loss in diabetic individuals using semaglutide.

approximately two-thirds

Weight Regain After Discontinuation

Proportion of weight regained within 12 months after discontinuation.

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Featured in

GLP-1 TherapiesIssue #34

Tirzepatide users had 18.4% weight loss vs 11.9% with semaglutide in head-to-head trial

↗

Semaglutide’s safety, effectiveness, and practical use for weight loss in adults without diabetes

Abstract

Key numbers

Full Text

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Related papers

Featured in

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief